Global epigenetic regulation and capsid delivery license agreement with Genentech

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time   BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 5, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2021 financial results.